Post authorization safety surveillance study (PASS) of hemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

被引：0

作者：

Parra Lopez, Rafael ^{[1
]}

Nemes, Laszlo ^{[2
,3
]}

Jimenez-Yuste, Victor ^{[4
]}

Rusen, Luminita ^{[5
]}

Cid, Ana R. ^{[6
]}

Charnigo, Robert J. ^{[7
]}

Baumann, James A. ^{[7
]}

Smith, Lynne ^{[7
]}

Korth-Bradley, Joan M. ^{[7
]}

Rendo, Pablo ^{[7
]}

机构：

[1] Univ Hosp Valle Hebron, Barcelona, Spain

[2] Natl Haemophilia Ctr, Budapest, Hungary

[3] State Hlth Ctr, Haemostasis Dept, Budapest, Hungary

[4] La Paz Univ Hosp, Madrid, Spain

[5] Natl Inst Transfus Hematol, Bucharest, Romania

[6] Univ Hosp La Fe, Thrombosis & Haemostasis Unit, Valencia, Spain

[7] Pfizer Inc, Collegeville, PA USA

来源：

HAEMOPHILIA | 2014年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：45 / 45

页数：1

共 9 条

[1] Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings
Parra Lopez, Rafael
Nemes, Laszlo
Jimenez-Yuste, Victor
Rusen, Luminita
Cid, Ana R.
Charnigo, Robert J.
Baumann, James A.
Smith, Lynne
Korth-Bradley, Joan M.
Rendo, Pablo
THROMBOSIS AND HAEMOSTASIS, 2015, 114 (04) : 676 - 684
[2] Assessment of incremental recovery over time in Post-authorization Safety Surveillance Study (PASS) of hemophilia A patients switching from moroctocog alfa or other Factor VIII products to moroctocog alfa Albumin-Free Cell Culture (AF-CC) in usual care settings
Korth-Bradley, Joan
Charnigo, Robert
Baumann, James
Smith, Lynne
Rendo, Pablo
HAEMOPHILIA, 2014, 20 : 23 - 24
[3] Evaluation of the safety and efficacy of recombinant factor VIII (moroctocog alfa [AF-CC]) in minimally treated and previously treated chinese patients with hemophilia A
Renchi, Y.
Zhao, Y.
Wang, X.
Sun, J.
Jin, J.
Wu, D.
Charnigo, R.
O'Brien, A.
Kollmer, C.
Rendo, P.
Zhong, Z.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 357 - 357
[4] BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.
Windyga, Jerzy
Rusen, Luminita
O'Brien, Amanda C.
Hayward, Brooke
Arkin, Steven
Roth, David A.
BLOOD, 2008, 112 (11) : 447 - 447
[5] An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A
Liu, Hongzhong
Wu, Runhui
Hu, Pei
Sun, Feifei
Xu, Lihong
Liang, Yali
Nepal, Sunil
Qu, Peng Roger
Huard, Francois
Korth-Bradley, Joan M.
CLINICAL THERAPEUTICS, 2017, 39 (07) : 1313 - 1319
[6] An Open-Label Study of the Safety and Efficacy of Morotocog Alfa (AF-CC) in Previously Untreated Patients Aged <6 Years in Usual Care Settings
Kavakli, Kaan
Baumann, James
Huard, Francois Pierre
Smith, Lynne
Alvey, Christine
Korth-Bradley, Joan
Rendo, Pablo
Rupon, Jeremy
BLOOD, 2017, 130
[7] Post-authorization safety surveillance (PASS) program of antihemophilic factor (recombinant), plasma/ albumin-free method (RAHF-PFM) for Japanese hemophilia A patients
Taki, M.
Fukutake, K.
Hanabusa, H.
Takamatsu, J.
Shima, M.
Shirahata, A.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1125 - 1125
[8] Data from a prospective post-authorization safety surveillance study in 384 hemophilia A patients in Japan with the antihemophilic factor (recombinant) plasma/albumin-free method demonstrates safety and efficacy
Fukutake, Katsuyuki
Hanabusa, Hideji
Taki, Masashi
Matsushita, Tadashi
Nogami, Keiji
Shirahata, Akira
HAEMOPHILIA, 2014, 20 : 18 - 18
[9] A post-marketing surveillance study of the safety and efficiacy of ReFacto® (Moroctocog Alfa, B-Domain deleted recombinant factor VIII) St. Louis-derived active substance in the treatment and prevension of bleeding episodes in hemophilia A patients.
Feingold, JM
Smith, MP
Littlewood, R
Giangrande, P
BLOOD, 2004, 104 (11) : 847A - 848A

← 1 →